The degrees of infiltration of CD4+ and CD8+ T cells in the tumors of immunocompetent mice were examined and indicated that the number of tumor-infiltrating CD8+ T cells was markedly increased after treatment with the TBK1 antagonist (Figure 7H). This evidence concerns the gene TBK1 and neoplasm.